Droperidols Grindex

Quick links

Choose a section

Quick links to important sections

Advertisements

Droperidols Grindex

Advertisements
Advertisements

Treatment option: Shock

Advertisements

Overview of Droperidols Grindex

Property Description
Active ingredient Droperidol
Form Solution for injection (Sterile, aqueous)
Pharmacological class Neuroleptic, Butyrophenone derivative
General purpose Tranquilization and Antiemesis
Origin Synthetic organic compound

What Type of Medicine is Droperidol (Droperidols Grindex)?

Droperidols Grindex is a potent, synthetic compound categorized as a first-generation antipsychotic and a type of neuroleptic agent. Its active ingredient, Droperidol, belongs specifically to the Butyrophenone derivative chemical class. This medicine is prescription-only, reserved for supervised use due to its profound, rapid effects on the central nervous system (CNS).

As a neuroleptic, the drug is primarily known for its ability to produce immediate, intense calming. Droperidol is clinically recognized for its efficacy in producing rapid tranquilization and sedation, a core differentiating feature for its use in acute care.

Composition and Physical Form

Droperidols Grindex is a single-ingredient product supplied as a clear, sterile solution for injection contained within an ampoule or vial. The active substance, Droperidol, is dissolved in an aqueous base/vehicle, a formulation designed for direct administration. The product is administered either intramuscularly or intravenously. The formulation as a sterile injection is a key differentiating feature, allowing for precise control and immediate action, unlike oral medications with delayed absorption.

General Purpose: Tranquilization and Antiemetic Action

The primary general purpose of Droperidol is to provide rapid sedation and tranquilization for patients requiring immediate, profound calming, such as stabilizing a patient experiencing extreme agitation. Furthermore, Droperidol possesses a powerful and distinct function as an antiemetic agent. Droperidol is used in managing postoperative nausea and vomiting, and is indicated for preventing and relieving feelings of nausea and the act of vomiting. This dual capability makes it a key adjunct in anesthesia.

Advertisements

What side effects are possible with Droperidols Grindex?

Possible Side Effects and Safety Information

This section details the officially documented adverse reactions and regulatory safety information for Droperidols Grindex, based on governmental prescribing documents.

Serious Adverse Reactions and Regulatory Warnings

Droperidol is subject to serious warnings due to the potential for QT interval prolongation and subsequent serious cardiac arrhythmias, including Torsade de pointes, ventricular tachycardia, cardiac arrest, and death. The FDA mandates a high-level warning concerning this cardiac risk. Another rare, but severe, reaction documented in regulatory labels is Neuroleptic Malignant Syndrome (NMS), characterized by altered mental status and muscular rigidity.

Frequency-Classified Adverse Events

Side effects are classified by their documented frequency in regulatory documents:

Classification Example Adverse Reaction System-Organ Class
Common Drowsiness, Hypotension Nervous System, Vascular
Uncommon Anxiety, Restlessness/Akathisia, Tachycardia Psychiatric, Cardiac
Rare Anaphylactic reaction, Cardiac arrhythmias Immune System, Cardiac

Additional neurological effects, such as Dystonia and Oculogyration (a type of extrapyramidal symptom), are also officially listed as Uncommon.

Safety Restrictions and Monitoring

Droperidol is contraindicated in patients with known congenital QT prolongation or any clinical condition that prolongs the QTc interval above 500 ms. The official labeling mandates that, when administered, patients must undergo ECG monitoring prior to treatment and for 2–3 hours following administration. Furthermore, any underlying hypokalemia or hypomagnesemia must be corrected beforehand.

Population-Specific Cautions exist, including the instruction to reduce the dose for elderly or debilitated patients. The safety and efficacy in children under 2 years of age have not been established.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Droperidol overdose is defined by its potential to cause a severe extension of its primary pharmacological effects, particularly on the central nervous and cardiovascular systems.

Documented Overdose Manifestations and Severe Outcomes

An overdose may result in profound tranquilization and deep sedation, accompanied by significant hypotension and the onset of Extrapyramidal symptoms (involuntary movement disorders).

The most severe concern, as stated in regulatory warnings, is cardiotoxicity. This includes QT interval prolongation and the risk of Torsade de pointes (TdP) and other serious arrhythmias, some of which have been reported as fatal. A critical outcome is the potential for Neuroleptic Malignant Syndrome (NMS), which is signaled by unexplained hyperthermia.

Emergency Action and Required Monitoring

Individuals must seek immediate medical attention for any symptom suggestive of irregular cardiac rhythm, such as palpitations or syncope, or for unexplained hyperthermia. Regulatory documents mandate that management is strictly symptomatic and supportive, as no specific chemical antidote is known. Required procedures include maintaining a patent airway and providing assisted respiration if needed. Furthermore, continuous ECG monitoring must be performed and continued for 2 to 3 hours after administration to monitor for the potential of delayed arrhythmias. The administration of Droperidol is explicitly contraindicated if a prolonged QT interval is present on a baseline ECG.

Advertisements

Therapeutic Uses of Droperidols Grindex

The therapeutic role of Droperidols Grindex focuses on two primary areas of symptomatic relief: acute behavioral stabilization and antiemetic support. This medication is considered relevant across therapeutic areas where short-term symptom management is appropriate.

Control of Severe Acute Agitation

This medication is applied in clinical settings that involve acute and unstable symptom patterns of severe agitation or aggressiveness where stabilization is necessary. It is commonly used across conditions characterized by periods of heightened symptoms, such as crisis episodes in acute care. Its therapeutic role is relevant for managing symptoms of heightened physiological activity by contributing to significant calming and sedation, which helps stabilize the acute situation and assists with maintaining functional stability.

Relief of Postoperative Nausea and Vomiting (PONV)

Droperidols Grindex is commonly used for managing conditions that present with symptomatic discomfort, specifically the distressing and disruptive symptoms of nausea and vomiting that arise in the postoperative recovery period following surgery. This medication helps address symptom clusters that may become intense or disruptive to recovery. The main benefit provided is supportive symptomatic relief, which contributes to improved comfort during periods of heightened symptoms.

“It is relevant across therapeutic areas where short-term symptom management is appropriate,” supporting the patient through difficult episodes.

Quick Fact: Supportive relief for acute agitation and postoperative emesis.

Regulatory References

  1. DailyMed (NIH/FDA) product information
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

The official eligibility profile for Droperidols Grindex is defined by strict exclusions, primarily related to cardiac risk and age.

Populations for whom use is allowed (as stated in label):

  • Adults (18 years and older) for specific indications.
  • Children and adolescents (generally mathbf2 to mathbf18 years of age) for specific indications, such as postoperative nausea and vomiting (PONV).

Populations for whom use is contraindicated:

  • Cardiovascular Conditions: Patients with known or suspected QT interval prolongation (e.g., QTc > 440 msec in males, > 450 msec in females), congenital long QT syndrome, or clinically significant bradycardia (slow heart rate) [1.5, 1.6].
  • Comorbidities: Individuals with Parkinson's Disease, severe depression, phaeochromocytoma, or those in comatose states [1.5, 1.6].
  • Physiological State: Patients with uncorrected hypokalaemia (low potassium) or hypomagnesaemia (low magnesium) [1.5, 1.6].

Age-Related Eligibility Rules:

  • Children Below Age 2 Years: Use is not recommended as safety and efficacy have not been established for this patient population [1.1, 1.6].
  • Geriatric Patients: The initial dose must be appropriately reduced [1.1, 1.6].

Condition-Specific Eligibility Restrictions:

  • Renal/Hepatic Impairment: Use requires caution and a reduced initial dose [1.1, 2.3].

Pregnancy and Lactation Eligibility Status:

  • Pregnancy: Use is limited to instances where the potential benefit outweighs the potential risk to the fetus (Category C or equivalent) [1.3].
  • Lactation (Breastfeeding): Caution should be exercised; some regulatory documents recommend limiting treatment to a single administration [1.3].

Connection to the overall eligibility profile:

Official regulatory documents define who can and cannot use the medicine by establishing absolute contraindications based primarily on cardiac risk factors and severe neurological conditions. Eligibility is further restricted by age, excluding children under 2 years, and requires special caution for older adults and individuals with impaired liver or kidney function [1.1, 1.6].

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Droperidols Grindex has formally documented interaction patterns primarily centered on pharmacodynamic effects, as described in official government regulatory documents.

Contraindicated Combinations

The co-administration of Droperidol is prohibited with medicines known to prolong the QT interval. This includes specific agents like Amiodarone, Sotalol, Quinidine, Ibutilide, and Pimozide. Combining these substances significantly increases the risk of serious cardiac arrhythmias, such as Torsade de pointes.

Pharmacodynamic Interactions

  • CNS Depressant Drugs: Co-administration with other Central Nervous System depressants, including Opioids, sedatives, and general anesthetics, may result in additive or potentiating effects leading to profound or prolonged sedation and respiratory depression.
  • Electrolyte-Altering Agents: Drugs that induce Hypokalemia or Hypomagnesemia, such as certain diuretics or laxatives, are regulatory concerns. This electrolyte imbalance is noted as a risk factor that can exacerbate Droperidol's effect on QT prolongation.
  • Epinephrine (Adrenaline): Due to Droperidol's alpha-adrenergic blocking action, administering Epinephrine may lead to a paradoxical decrease in blood pressure (hypotension).

Interaction-Related Constraints

For concurrent use with Opioid analgesics, regulatory documents state that an appropriate reduction of the initial dose of the Opioid is required. Furthermore, the consumption of alcohol (ethanol) is noted to increase the risk of an irregular heart rhythm. Special caution is noted for patients with Impaired Hepatic or Renal Function due to potential changes in drug clearance.

Advertisements

Mechanism of Action

Droperidol is a butyrophenone derivative that functions primarily as a non-selective central nervous system depressant. Its mechanism involves antagonism at several key neuroreceptors.

Neuroreceptor Targeting

The principal biological targets are the dopamine type 2 (D2) receptors, particularly those located in the subcortical levels of the brain and the chemoreceptor trigger zone of the brainstem. Droperidol competitively binds to and blocks these G-protein-coupled receptors, inhibiting the stimulatory effects of dopamine. The blockade of D2 receptors is mediated by the Gi-coupled protein pathway, which typically leads to an inhibition of adenylyl cyclase activity, thereby decreasing the intracellular concentration of cyclic adenosine monophosphate (cAMP).

Droperidol also acts as an antagonist at alpha-1 adrenergic receptors in both the central and peripheral nervous systems. Antagonism of peripheral alpha-1 receptors leads to vasodilation by preventing norepinephrine-induced smooth muscle contraction, resulting in a reduction of peripheral vascular resistance and systemic arterial pressure.

Advertisements

Dosage and Administration Information

Droperidols Grindex is supplied as a sterile solution for injection (2.5 mg/mL) intended for parenteral administration only, primarily via Intravenous (IV) or Intramuscular (IM) routes. Dosage must be individualized based on the patient’s clinical status and is strictly for short-term use in acute settings. The solution must be visually inspected for discoloration or particulate matter prior to use.


Standard Labeled Dosing Regimens

Indication Adult Dose Range Frequency and Timing
Postoperative Nausea & Vomiting (PONV) 0.625 mg to 1.25 mg IV Administered 30 minutes prior to the anticipated end of surgery, repeatable every 6 hours as required.
Acute Agitation/Aggressiveness 2.5 mg to 5 mg IV or IM (single dose) Additional doses may be given with at least 20 minutes elapsed time. The total dose must not exceed 20 mg in a 24-hour period.

Administration Guidelines and Adjustments

For the intravenous route, the medicine must be administered via slow injection, typically over at least one minute. Due to its potency, the drug is administered under close clinical supervision in a monitored setting.

Lower initial doses are specified for certain groups. For PONV, a dose of 0.625 mg IV is indicated for older adults (over 65 years) and patients with renal or hepatic impairment. For children (2–18 years), the PONV dose is based on body weight, using a range of 10 to 50 micrograms per kilogram up to a maximum of 1.25 mg. The drug is not recommended for use in children under two years of age.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Droperidols Grindex


Evidence for Use in Severe Acute Agitation

Research has explored the use of Droperidols Grindex in acute care settings for people experiencing severe agitation, aggression, or violent behavior. The research is primarily based on Randomized Controlled Trials (RCTs), where the medicine was evaluated in comparison against a placebo or other sedative drugs, with findings summarized in Systematic Reviews that combine data from many studies.

These studies focused on measuring outcomes related to episodic or acute changes in behavior. Researchers examined how quickly the medicine was observed for its role in achieving a state of tranquilization or adequate stabilization. They also monitored how many patients needed rescue sedation—additional medication—within the initial hours of treatment. The findings describe patterns observed in the studies regarding the time required to achieve the acute behavioral stabilization endpoint.

Research was evaluated in adults experiencing these periods of heightened symptom activity, but long-term effects are not fully established. The data are still emerging regarding the management of agitation beyond the acute stabilization phase.


Evidence for Use in Postoperative Nausea and Vomiting (PONV)

The research has explored its use for nausea and vomiting that follows surgery across a significant number of trials. This body of evidence includes comparative Randomized Controlled Trials and detailed Network Meta-Analyses which has explored this medicine for both the prevention (prophylaxis) and treatment of these outcomes related to physical discomfort.

Research monitored the incidence of nausea and vomiting in surgical patients and measured the need for rescue antiemetic medication. Studies report how symptoms evolved in the observed populations across the early (up to 6 hours) and later (up to 48 hours) postoperative periods. This evidence contributes to the broader evidence landscape for antiemetic agents in the postoperative setting.


Research Gaps and Areas of Uncertainty

Research was evaluated in specific indications, but certainty remains low in other areas. For example, while the evidence for PONV prevention is extensive, comparative evidence for the treatment of established nausea and vomiting is less numerous.

Furthermore, research highlights what is known — and what is still uncertain — regarding specific populations. Subgroup findings are uncertain for pediatric and geriatric patients because sample sizes were modest in the available trials. The findings describe group patterns, not personal outcomes, and it is important to understand that the results apply only to the populations studied and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. DROPERIDOL injection, solution (Official Monograph and Labeling Information)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Droperidols Grindex (FAQ)

Q: What is Droperidols Grindex used for?

Droperidols Grindex is an injectable medicine that belongs to a class of drugs called neuroleptics (antipsychotics). It is primarily used to prevent and treat nausea and vomiting following surgery or during medical procedures. It can also be used as a sedative to calm agitation.

Q: How is Droperidols Grindex administered?

Droperidols Grindex is administered as a deep intramuscular injection (into a large muscle) or as a slow intravenous injection (into a vein). It must be administered by a healthcare professional in a hospital or clinical setting. It is not available for self-administration at home.

Q: What should I tell my doctor before receiving Droperidols Grindex?

Tell your doctor if you:

  • Have or have had a condition that causes an irregular heartbeat (e.g., congenital long QT syndrome).
  • Have low potassium or magnesium levels in your blood.
  • Have a slow heartbeat (bradycardia).
  • Are taking other medications that affect the heart rhythm.
  • Have severe liver or kidney problems.
  • Are pregnant, planning to become pregnant, or breastfeeding.
  • Have Parkinson's disease.

Q: What are the possible side effects of Droperidols Grindex?

The most common side effects include:

  • Sleepiness or sedation.
  • Low blood pressure (hypotension), which may cause dizziness.
  • Irregular heartbeat (QT prolongation).
  • Dizziness or lightheadedness.
  • Anxiety or restlessness.
  • Involuntary muscle movements or tremors.

Serious side effects are rare but can include a severe reaction called Neuroleptic Malignant Syndrome (NMS), characterized by fever, muscle rigidity, and changes in mental status. You will be monitored closely for these effects during and after administration.

Advertisements

How should Droperidols Grindex be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal of Droperidol Injection must strictly adhere to the conditions documented in regulatory labeling to maintain product stability and safety.

Condition Requirement
Temperature Store at 20° to 25°C (Controlled Room Temperature).
Protection Must be stored in the original package to protect from light.
Child Safety Keep the medicine out of the sight and reach of children.

This medication is for single use only. Any unused portion remaining in the ampoule or vial must be discarded immediately after use. For disposal of expired or unused medicine, either use a drug take-back program or follow the official procedure of mixing the drug with an undesirable substance (e.g., dirt) before sealing it for household trash. Needles and syringes (sharps) must be disposed of in a designated, puncture-resistant container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Droperidols Grindex found in:

A-Z Index: